Soligenix announces appointment of timothy r. cotÉ, m.d.

Strengthens regulatory and orphan drug development expertise princeton, n.j. , may 3, 2023 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of timothy r.
SNGX Ratings Summary
SNGX Quant Ranking